Karuna Therapeutics Inc

NASDAQ:KRTXUnited States

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Contact Information

Headquarters

99 High Street, 26Th FloorBOSTON, MA, United States 02110

Phone

857-449-2244

Fax

302-636-5454

Executives

Director

Steven Paul

Chief Financial Officer, Company Secretary

Troy Ignelzi

Chief Operating Officer

Andrew Miller

Chief Medical Officer

Stephen Brannan

Chief Commercial Officer

Charmaine Lykins